Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.50 |
| ▸ | SPHK2 | Q9NRA0 | 5/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | NAAA | Q02083 | 6/20 | 0.41 |
| ▸ | SPHK1 | Q9NYA1 | 4/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23014720 | 0.98 | CYP1A2 (0.56) | CYP1A2SIGMAR1SPHK2EPHX1NAAA | |
| SCHEMBL23014885 | 0.94 | CYP1A2 (0.50) | CYP1A2SIGMAR1SPHK2EPHX1NAAA | |
| SCHEMBL6437482 | 0.92 | CYP1A2 (0.64) | CYP1A2SIGMAR1EPHX1NAAA | |
| SCHEMBL18874584 | 0.90 | SPHK2 (0.47) | CYP1A2SIGMAR1SPHK2SPHK1 | |
| SCHEMBL18512394 | 0.90 | SPHK2 (0.47) | CYP1A2SIGMAR1SPHK2SPHK1 | |
| SCHEMBL29101112 | 0.87 | SIGMAR1 (0.56) | CYP1A2SIGMAR1SPHK2EPHX1NAAA | |
| SCHEMBL14740174 | 0.87 | SIGMAR1 (0.56) | CYP1A2SIGMAR1SPHK2EPHX1NAAA | |
| SCHEMBL23014969 | 0.86 | CYP1A2 (0.56) | CYP1A2SIGMAR1SPHK2EPHX1NAAA | |
| SCHEMBL22857774 | 0.86 | CYP1A2 (0.61) | CYP1A2SIGMAR1SPHK2NAAASPHK1 | |
| SCHEMBL6937266 | 0.85 | CYP1A2 (0.54) | CYP1A2SIGMAR1SPHK2EPHX1NAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220298185-A1 | Nucleoside Prodrugs and Uses Related Thereto | UNIV EMORY (US) | 2022-09-22 | — | — | US | claimed |
| EP-4017499-A1 | NUCLEOSIDE PRODRUGS AND USES RELATED THERETO | Emory University (US) | 2022-06-29 | — | — | EP | claimed |
| WO-2021035214-A1 | NUCLEOSIDE PRODRUGS AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2021-02-25 | — | — | WO | claimed |
| EP-0254540-A2 | Glycerol derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1988-01-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220298185-A1 | Nucleoside Prodrugs and Uses Related Thereto | PNPO, GSTO1, CYP2C18 | CYP1A2 38/4885SIGMAR1 1651/4885SPHK2 2404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.